Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 27, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,100,000 ordinary shares.
- Purchase Price: 1,314.71 pence per share.
- Treasury Holdings: 324,174,158 shares (representing 5.69% of total voting rights).
- Shares in Issue: 5,696,643,157 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the June 27, 2007 purchase. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly serves as a notification of the share buyback and the resulting capital structure adjustments under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (324,174,158) and the percentage of voting rights represented (5.69%).
- Confirm the total number of shares in issue excluding Treasury shares (5,696,643,157) for disclosure threshold calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.